Keywords: abbott, enanta, begin, ph, hcv, trial, usa
Abbott and Enanta to begin Ph I HCV trial
Article | 23 February 2009
The USA's Abbott Laboratories and Enanta Pharmaceuticals have begun a first-in-human study evaluating ABT-450, an oral protease inhibitor for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
